{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"16.000","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"375,457,818","primaryexch":"香港交易所","ric":"2410.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BQ1N021","am":"87.62","iv":"","ew_strike":"","as":"15.570","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"15.550","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"13.000","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"吳豫生","underlying_ric":"2410.HK","hi52":"56.550","issuer_name":"浙江同源康醫藥股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"15.280","mkt_cap":"5.83","f_aum_hkd":null,"ew_sub_per_to":"","ls":"15.550","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.270","aum":"","issued_shares_class_B":null,"vo":"5.62","secondary_listing_flag":false,"listing_date":"2024年8月20日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"浙江同源康醫藥股份有限公司 - B - H股","nm_s":"同源康醫藥－Ｂ","sym":"2410","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"浙江同源康醫藥股份有限公司是一家致力於開發及商業化醫藥產品的中國公司。該公司專注於小分子藥物開發，其主要產品包括TY-9591、TY-302和TY-2136。TY-9591是一種第三代EGFR-TKI，對EGFR突變具有抗腫瘤作用。TY-302是一種為治療乳腺癌及前列腺癌等晚期實體瘤而開發的強效、選擇性口服CDK4/6抑制劑。TY-2136b為自主研發、口服ROS1/NTRK抑制劑，用於治療實體瘤。","op":"15.600","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國上海市徐匯區<br/>龍蘭路277號<br/>東航濱江中心<br/>T2幢8樓","pc":"-1.71","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"15.820","isin":"CNE100006L34","moneyness":""}},"qid":"1759074167424"}
